Scholarlink

<p>We formulated a micellar nanosystem for selective differentiation therapy of breast cancer stem cells (BCSCs). Hyaluronic acid (HA) coating was used to target CD44<sup>+</sup> BCSCs, while codelivery of all-trans retinoic acid (ATRA) and histone deacetylase inhibitor (HDACi) was used to revert epigenetic silencing of the RARβ gene, sensitizing resistant tumor cells to treatment. Nanomicelles were formulated using the thin‑film hydration (TFH) method. The anti-cancer effects of nanoparticles (NPs) were evaluated on MDA-MB-231, MDA-MB-468, MCF-7 and MCF10-A cell lines with different stemness properties. The size of the NPs HA-PF127@ATRA, HA-PF127@SB and HA-PF127@ATRA@SB were determined to be 32.02&#xa0;nm, 47.46&#xa0;nm and 52.10&#xa0;nm, respectively. HA-PF127@ATRA@SB NPs mitigated ATRA resistance in MDA-MB-231 cells, significantly inhibited migration, promoted maximum spheroid size reduction, and achieved lower IC<sub>50</sub> values compared to the blank drugs. Importantly, it reduced stemness markers ALDH1A1, CD24 and restored retinoic acid receptor beta (RARβ) gene expression in MDA-MB-231 cells, whereas opposite trends were observed in MDA‑MB‑468 and MCF‑7 cells. Finally, nanomicell therapy favored the induction of late apoptosis in MDA-MB-231 cells, while most of the MDA-MB-468 and MCF-7 cells were in the early apoptosis phase. The nanomicelles demonstrate favorable physicochemical characteristics, and elicit maximum and tumor-specific anti-cancer effects based on differentiation therapy upon BCSC-enriched tumors.</p> Graphical abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Engineered pluronic nanomicelles containing ATRA and sodium butyrate for selective TNBC differentiation therapy

  • 期刊论文

  • 发表日期：

    2025年12月26日

查看全文
  • Abolfazl Doustmihan,
  • Mehdi Jaymand,
  • Marziyeh Fathi,
  • Rana Jahanban Esfahlan

摘要

We formulated a micellar nanosystem for selective differentiation therapy of breast cancer stem cells (BCSCs). Hyaluronic acid (HA) coating was used to target CD44+ BCSCs, while codelivery of all-trans retinoic acid (ATRA) and histone deacetylase inhibitor (HDACi) was used to revert epigenetic silencing of the RARβ gene, sensitizing resistant tumor cells to treatment. Nanomicelles were formulated using the thin‑film hydration (TFH) method. The anti-cancer effects of nanoparticles (NPs) were evaluated on MDA-MB-231, MDA-MB-468, MCF-7 and MCF10-A cell lines with different stemness properties. The size of the NPs HA-PF127@ATRA, HA-PF127@SB and HA-PF127@ATRA@SB were determined to be 32.02 nm, 47.46 nm and 52.10 nm, respectively. HA-PF127@ATRA@SB NPs mitigated ATRA resistance in MDA-MB-231 cells, significantly inhibited migration, promoted maximum spheroid size reduction, and achieved lower IC50 values compared to the blank drugs. Importantly, it reduced stemness markers ALDH1A1, CD24 and restored retinoic acid receptor beta (RARβ) gene expression in MDA-MB-231 cells, whereas opposite trends were observed in MDA‑MB‑468 and MCF‑7 cells. Finally, nanomicell therapy favored the induction of late apoptosis in MDA-MB-231 cells, while most of the MDA-MB-468 and MCF-7 cells were in the early apoptosis phase. The nanomicelles demonstrate favorable physicochemical characteristics, and elicit maximum and tumor-specific anti-cancer effects based on differentiation therapy upon BCSC-enriched tumors.

Graphical abstract